Biocytogen Pharmaceuticals Beijing
My visitor profile
Biocytogen Pharmaceuticals Beijing
Description of your activity
- A clinical-stage Biotech committed to becoming a global headstream of new antibody drugs with proprietary fully human antibody discovery RenMice™ platforms. Biocytogen has launched Project Integrum, the world’s first large-scale antibody discovery screening program adopting an evidence-based in vivo efficacy screening methodology to concurrently generate and screen antibodies against over 1,000 potential druggable targets, including BIC/FIC mAbs/BsAbs/BsAb-ADCs/TCRm Abs/GPCRs.
More information
-
Highlights:
- Recent bsADC deals: YH012 (HER2 x TROP2) with Radiance, B7H3 x PTK7 with Ideaya
- 10 fully human bsAbs at PCC/IND stage, e.g. CTLA-4 x OX40, OX40 x OX40
- 200+ TAA targets for “plug & play”
- 20+ Bispecific ADCs with improved anti-tumor efficacy in preclinical studies, featuring BCG033: PTK7 x TROP2, BCG022: HER3 x MET
- Most advanced bsADCs are in phase I
- Trispecific TAA-CD3-4-1BB TCEs with enhanced T cell function and reduced safety risk
- 10+ TCRm antibodies targeting intracellular TAAs including WT-1, KRAS, P53, AFP, GP100 NY-ESO-1, etc.
- 100+ Nanobody initiatives, including BBB-crossing assets for CNS therapies
- 7 innovative discovery platforms to generate different formats: fully human antibody mAb, common light chain bsAbs and bsAb-ADCs, nanobodies, TCR mimics, GPCR-targeting mAbs, and fully human TCRs
- Platform licensing with Merck, BeiGene, Janssen, etc.
- 1,000+ antibody target hits: targeting oncology, inflammatory and autoimmune diseases, infectious diseases, and neurodegenerative disease applications
Social Networks
Mature Company
Boyao ZHANG
Senior manager business development & licensing
Main sector
- Biotechnology - Therapeutics and Diagnostics
Address
- Country : CHINA
- City : Beijing
- Zip Code : 102609
Participation objectives
Partnering objectives
- In-licensing / collaboration opportunities, Out-licensing / collaboration opportunities, Network development
Description of my participation objective
Communication materials
